Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Across the ladder, receptor engagement rises about sixfold from the starter dose to the top, and weight loss rises with it
Targeting aging hallmarks in IPF could unlock therapies for a spectrum of chronic diseases, transforming how we approach aging and drug development
Researchers in China synthesized an optical-magnetic multimodal probe targeting TfR1, a ferroptosis-specific molecular marker, and employed molecular imaging technology to achieve dynamic visualization and monitoring of tanshinone IIA efficacy in treating myocardial ischemia/reperfusion injury and elucidating ferroptosis pathway regulatory mechanisms
vitamin D intake ~20% of recommendations Lean mass risk: protein + calcium insufficiency may contribute, alongside other drivers B-vitamins: thiamine and cobalamin deficits appear to increase over time Clinical takeaway (my approach): GLP-1s dont cause malnutrition in everyone but they can unmask risk in the wrong context (older adults, low-protein diets, restrictive eating patterns, prolonged nausea/vomiting, rapid weight loss, post-bariatric patients)
Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal conditions like gastroparesis may rule out tirzepatide and similar GLP-1 based therapies
